Fusco et al. showed that luminal B-like MMR-deficient breast carcinomas have a shorter overall survival than those with proficient MMR, while patients with ER-negative BC treated with chemotherapy lived longer with MMR deficiency [10]. Here, MRC1 is linked to breast carcinoma.